The control of malaria is challenged by drug resistance, and new antimalarial drugs are needed. New drug discovery efforts include consideration of hybrid compounds as potential multi-target antimalarials.
Introduction
Several concerted efforts to control malaria and achieve its eradication have been made through history. 1 Despite initial success, with regional elimination in Southern Europe and some countries in North Africa and the Middle East, malaria has not been controlled in many other countries due to a number of factors. 2 Two main reasons behind malaria remaining such a burden to humanity are the widespread resistance of the malaria parasite to available drugs and its complex life cycle. 2 Human malaria is triggered by infection by an intracellular Plasmodium parasite, which is transmitted to human hosts via an infected female Anopheles mosquito bite. Once in the host circulation, Plasmodium sporozoites initiate the asexual phase of the life cycle by quickly moving to the liver. During this clinically silent liver-stage infection, thousands of merozoites are formed and released into the bloodstream, where they invade red blood cells, thus starting the pathogenic asexual erythrocytic cycle, resulting in the various clinical manifestations of malaria. 3 Resistance of malaria parasites to previous generations of medicines, such as chloroquine (1), became widespread in the 1970s and 1980s, undermining malaria control efforts. During the last decade, artemisinin-based combination therapies (ACTs) have been adopted globally as the first line of treatment.
ACTs include a rapidly acting artemisinin component and a partner drug to improve efficacy and hinder emergence of resistance to artemisinins. 4 However, there are now worrisome signs that malarial parasites are developing resistance to artemisinins (2) , 5 and so the dependence of all new drug combinations on artemisinin derivatives is a matter of concern. While most available antimalarial agents target the bloodstage parasites, relatively few drugs are known to inhibit liver stage parasites. Primaquine (3) remains the only drug in clinical use worldwide that acts against liver stages of all Plasmodium species, 6 including P.
vivax and P. ovale hypnozoites, which are latent forms unique to these species that cause relapsing malaria long after the original infection, complicating control efforts. 7, 8 Taking into account concerns of drug resistance and difficult-to-treat chronic liver stages, optimal therapy should be effective against multidrug-resistant parasite strains and be active against both liver and erythrocytic parasite stages.
A recent approach in antimalarial drug design characterized as "covalent bitherapy" involves linking two active molecules, thus packaging dual activity into a single hybrid molecule with potential to enhance efficacy, improve safety and/or reduce propensity to elicit resistance relative to the parent drugs. 9, 10 As part of our efforts to develop novel hybrids, we previously reported a first-generation of heterocycliccinnamic acid conjugates (4 and 5, Figure 1 ), linking the heteroaromatic ring of known antimalarials to a trans-acid cinnamic motif, active in vitro against blood-stage P. falciparum. 11 From these studies we discovered that a spacer between the heterocycle and the cinnamoyl moiety is required for antiplasmodial activity and that the higher the lipophilicity of conjugates 4, the higher their in vitro antiplasmodial activity. Based on these results, we developed a second-generation of conjugates (7 and 8, Figure 1) where the cinnamoyl core was linked to the heterocyclic core of known antimalarials through a flexible and more hydrophobic butylamine chain. 12, 13 Compounds 7 (IC 50 against cultured malaria parasites: 11 -59 nM) 13 and 8 (IC 50 : 1.4 -2.4 µM) 12 had higher in vitro potency than their parent compounds, 1 (IC 50 :
138 nM) and 3 (IC 50 : 7.5 µM), against blood-stage P. falciparum (W2 strain) and liver-stage P. berghei.
These findings established the cinnamoyl core as a valuable pharmacophore to enhance potency of established antimalarials.
Building on these compounds, we have performed further SAR studies and herein report the synthesis and antimalarial assessment of a series of new heterocyclic-cinnamic conjugates (in brief, HEFLECINs). In terms of SAR, the presence of aromaticity in the heterocyclic core, the number of the heteroaromatic rings, the length of the aliphatic chain, the nature (amide or ester) of the linkage between the heterocycle and cinnamic core and the nature of the cinnamic substituent were all evaluated ( Figure 2 ). Compounds were tested in vitro against erythrocytic stages of the human parasite P. falciparum; two of them, 7d and 7h, were further confirmed to be active in vivo against the clinically relevant blood-stage infection in a P. 
, followed by addition of PQ. Compounds 7 13 and 9-13 were obtained in two steps, starting from (i) a classical nucleophilic aromatic substitution reaction between the appropriate diaminoalkane (1,3-diaminopropane, 1,4-diaminobutane or 1,5-diaminopentane) or 4-aminobutan-1-ol (in the synthesis of 11) and the desired chlorinated heterocycle (4,7-dichoroquinoline, 4-chloroquinoline or 4-chloropyridine), followed by (ii) coupling the resulting compounds to the appropriate cinnamic acids, again conveniently activated by TBTU/DIEA. The synthesis of 14 was the only one requiring three steps, as (i) morpholine was first reacted with 1-(N-phthaloyl)amino-4-bromobutane, followed by (ii) hydrazinolysis of the phthaloyl amino-protecting group, to afford the free amine for subsequent (iii)
PyBOP/DIEA-mediated coupling to the appropriate cinnamic acid.
Although not all synthesis yields were high, the rather small number of synthesis steps, cheap starting materials and straightforward purification techniques (cf. Experimental Section) largely compensate for low yields. All the target compounds where obtained in high purity, as determined by high performance liquid chromatography with diode array detection (HPLC-DAD), and their structures were confirmed by proton ( 1 H-) and carbon-13 ( 13 C-) nuclear magnetic resonance (NMR), as well as by mass spectrometry (MS) analysis with electrospray ionization and ion-trap quadrupole detection (ESI-IT); relevant data are presented in the Experimental Section.
Biology. Our recent discovery of the potent in vitro activity of CQ analogues 7 against blood-stage CQresistant P. falciparum parasites unveiled the key role of the cinnamoyl moiety in reversing parasite resistance to CQ. 13 We have now expanded the family of heterocyclic-cinnamic acid conjugates (HEFLECINs) and tested their in vitro activity against blood-stage P. falciparum (Table 1) , in order to (i) establish relevant SAR (Figure 2) , and (ii) select the most promising candidates for in vivo challenge in the P. berghei rodent malaria model. For some of the compounds we compared activity against chloroquine-sensitive (3D7) and -resistant (W2) P. falciparum parasites. Furthermore, given their structural analogy to CQ, which acts via inhibition of β-hematin formation, selected compounds were evaluated as in vitro inhibitors of this process (Table 1) . 14, 15 Finally, based on our latest disclosure of primaquine-cinnamic acid conjugates (PRIMACINs) with improved in vitro activity against liver-stage Plasmodia, 12 we also assessed the in vitro activity of a subset of the HEFLECINs against liver-stage P.
berghei ( Figure 3 , Table 1 ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In vitro activity against intraerythrocytic P. falciparum parasites. Blood-stage activity of HEFLECINs was determined by methods previously reported by us. 16, 17 Close inspection of our data (Table 1, columns 8 and 9) shows the following.
(i) Remarkably, most of the test compounds assayed against both strains were more active against the CQ-resistant (W2) strain than against the CQ-sensitive (3D7) strain.
(ii) Compounds from the 7, 9 and 10 series with a single substituent (R) on the cinnamoyl group (i.e., all except 7p) were highly active, with IC 50 s in the range of 11-79 nM. shows that a butyl spacer is preferred over pentyl and propyl spacers.
(iii) Removal of the 7-chlorine substituent from the chloroquinoline ring leads to a decrease in antimalarial activity of about one order of magnitude, as shown for compounds 7c (IC 50 11 nM) and its dechlorinated analogue 12 (115 nM).
(iv) Replacement of the amide bond in 7d (IC 50 20 nM) by its ester isostere, to afford 11, leads to a sixfold decrease in activity (122 nM).
(v) Substitution of the chloroquinoline ring (e.g. 7d, IC 50 ~ 20 nM) by another heteroaromatic ring, either quinolinic (8-amino-6-methoxyquinoline ring in 8d), pyridinic (single heteroaromatic pyridine ring in 13)
or non-aromatic (morpholine ring in 14), leads to complete loss of activity.
(vi) Comparison of IC 50 values within a given series, e.g. compounds 7 or 9, shows that the cinnamoyl substituent R has some effect on activity, but that this effect is not dramatic. The electrodonating/withdrawing character of R seems to have no significant role in activity, whereas the para position is clearly preferred over the ortho or meta positions, as shown for 7k-l and 9k-l. 21 (vii) Increase in compound lipophilicity and/or the bulkiness of R within a series seems to enhance in vitro activity. We previously showed that IC 50 values for compounds 7 showed good correlation with both clogP values and Charton parameters. 13 For the new 9 series, we observed a good correlation with Charton parameters, but not clogP values (cf. Table S1 provided as Supporting Information). Series 10 was too small to allow drawing definitive conclusions in this regard.
(viii) Finally, HEFLECINs bearing the chloroquinoline core were globally more active than CQ, whereas the two most active compounds, 7c and 7h, had activities comparable to that of artemisinin. Therefore, these two compounds, as well as 7d, the most active compound within the series satisfying the leadlikeness, 18 Lipinski 19 and Veber 20 filters, were selected for in vivo studies with P. berghei.
In vitro activity against β β β β-hematin formation. The ability of HEFLECINs to inhibit β-hematin formation to hemozoin, the main mechanism attributed to CQ and related antimalarials, was assessed by previously reported methods. 11 This activity was not fully correlated with in vitro antimalarial activities ( Table 1 ), suggesting that HEFLECINs owe their antimalarial properties to mechanisms in addition to inhibition of β-hematin crystallization. Nonetheless, we believe that inhibition of β-hematin formation contributes to activity because (i) variation of β-hematin inhibition potency amongst homologues, e.g., 7c, 9c and 10a follows the same trend as variation of activities against blood-stage parasites and (ii) the significant decrease in antimalarial activity upon removal of the 7-chlorine substituent (7c vs. 12) may be explained by the prior observation that this chlorine atom is essential to ensure effective β-hematin inhibition by CQ and related structures. 21, 22 Based on previous and current findings, it is concluded that HEFLECINs do not act against blood-stage parasites via inhibition of the cysteine protease falcipains. 13 Activity may include impairment of the New Permeation Pathways (NPP) created by Plasmodia in the infected red blood cell (RBC) 13 and inhibition of β-hematin crystallization. were 7c and 7h due to their potency against cultured blood-stage P. falciparum and 7d due to its better drug-likeliness. Mice were infected intraperitoneally (ip) with P. berghei and then treated twice daily with ip injections of 10, 30 and 100 mg/kg. Chloroquine was used as a positive control at 3, 10 and 30 mg/kg ip twice daily. All mice died due to malaria or toxicity by day 17 at the doses administered. In order to compare compound efficacies, survival over time after the initiation of treatment was compared.
Close inspection of the data leads to the following observations ( Figure 3 ). Compounds 7c and 7h were highly toxic at 100 mg/kg, and no mice survived until the last day of treatment. At lower dosages, 7h
extended survival compared to untreated controls by 2-7 days at 30 mg/kg and by 2 days at 10 mg/kg.
Compound 7c did not improve survival compared to untreated controls. Compound 7d did not appear to be toxic at any tested dosage. It extended survival by 2 days compared to untreated controls at the highest dosage, but offered no benefit over untreated controls at the lower dosages.
Studies with the rodent malaria model confirmed that 7d and 7h have in vivo antimalarial activity. The lack of in vivo activity of 7c can be attributed to its high lipophilicity (clogP > 5, see Table S1 on SI), 19 but compounds 7d and 7h are only slightly less lipophilic (clogP ~5, see Table S1 on SI) than 7c.
However, in vivo activities for 7d and 7h were lower than might be expected based on their in vitro activities, possibly due to limitations in bioavailability. Additionally, relatively poor performance of the compounds in vivo might be explained by biological differences between P. berghei and P. falciparum and by the high hydrophobicity of the compounds, which might result in extensive binding to plasma proteins. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59Table 1 . In vitro data on test compounds for β-hematin inhibition, and blood and liver stage activity.
Pf W2 IC50 (nM) [b] Pf 3D7 IC50 (nM) [b] Liver Stage IC50 (µM) [c] 7.5
[h]
[a] ability of the test compounds to inhibit hemozoin formation in vitro was calculated as a % of the inhibitory effect displayed by reference drug CQ in the same experiment; test compounds were ranked as follows: <50%, not active (-); between 50 and 75%, moderately active (+); ≥75%, highly active (++);
[b] blood-stage antiplasmodial activity was determined against the CQ-resistant P. falciparum strain W2 and strain 3D7, using 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 In vitro activity against liver-stage P. berghei parasites. Recent findings from our group, demonstrating that the liver-stage activity of PQ is significantly enhanced by conjugation with cinnamic acids, prompted us to investigate whether HEFLECINs would also exhibit liver stage activity, measured using P. berghei as previously reported. 12, 17, 25 We found that HEFLECINs bearing the chloroquinoline core of CQ (7, 9, 10) were all active against liver stage parasites. This result was surprising, as CQ is not active against liver-stage malaria 26 . In view of these results, the activities of compounds selected as most promising based on activity and cytotoxicity, were compared quantitatively ( Figure 4 , Table 1 ). Remarkably, activities were much higher than those observed for either CQ or PQ. Specifically, IC 50 values were 5-15 times lower than those for CQ, and 3-7 times lower than those for the reference drug PQ. This is, to our knowledge, the first report of 4-amino-7-chloroquinolinic (CQ-related) structures displaying in vitro activity against liver-stage Plasmodia greater than that of PQ. This finding, together with the previous observation that N-cinnamoylation of PQ also enhances its in vitro activity against liver-stage Plasmodia, 12 strongly suggests that the N-cinnamoyl moiety is a relevant pharmacophore to boost antiplasmodial activity in both 8-and 4-aminoquinolines. Some SAR could be devised from the liverstage assays, as follows:
(i) As in blood-stage activity assays, a butyl spacer between the chloroquinoline and the cinnamic cores is generally preferred over propyl and pentyl spacers, both in terms of activity and toxicity, as inferred from comparison of homologues from series 7, 9 and 10.
(ii) Unlike what was observed in blood-stage activity assays, substitution of the cinnamoyl aromatic ring in series 7 led to slightly decreased activity, i.e., the most active compound was 7a, where R = H.
(iii) The presence of electrodonating R groups in the para position led to a decrease in activity.
(iv) An increase of the number of OMe substituents on the cinnamoyl core from one (7d) to two (7p) led to a decrease in toxicity, but also in activity. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 (v) Removal of the 7-chlorine atom from the chloroquinoline ring led, as observed for blood-stage activity, to a decrease in liver-stage activity.
(vi) Also as observed against blood-stage Plasmodia, replacement of the chloroquinoline ring by pyridine or morpholine led to loss of activity against liver-stage parasites.
As is the case for PQ, the mechanism of HEFLECINs against liver-stage Plasmodia remains to be elucidated. 12 Studies are under way to establish the target(s) of HEFLECINs against liver-and bloodstage parasites. The discovery that HEFLECINs bearing the CQ heterocyclic core, unlike their PQ analogues (PRIMACINs 12 ), combine significant liver-stage activity with potent blood-stage activity, is of great interest. To our knowledge, this is the first example of CQ-related molecules emerging as multistage antimalarial leads. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60
Concluding remarks
A new family of chloroquine analogues, HEFLECINS, as dual-stage antimalarial leads, was found. These compounds display potent in vitro activity against both liver-and blood-stage Plasmodia, Overall, data show that N-cinnamoylation of chloroquine enhances the parent drug's activity against both blood-and liver-stage Plasmodia, which is the first example of chloroquine-derived molecules with multi-stage antimalarial activity. This finding, along with the recent disclosure of an apparent resusceptibilization of P. falciparum to chloroquine in Nigeria, 29 may have relevant impact on the reactivation of chloroquine manufacturers, especially in African countries like Ghana, in which chloroquine production has been halted due to the well-known parasite resistance to this drug. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Synthesis of compounds 7-10. Compounds 7a-l and 8 were prepared by previously described methods, and their analytical and structural data were in perfect agreement with formerly reported data. 12, 13 . Compounds 7o,p were prepared identically to 7a-l and their spectroscopic data were compatible with the respective structures, as follows. Compounds 9 and 10 were synthesized by methods similar to those previously described for compounds
4-[N-(p-dimethylamino)cinnamoylaminobutyl]amino-7-chloroquinoline (7o):

7;
13 briefly, 4,7-dichloroquinoline (1 eq, 1.2 mmol) was reacted with the appropriate diaminoalkane (10 eq, 12 mmol) at 100 ºC for 3 h; the mixture was brought to room temperature and then diluted with dichlorometane (DCM), and the resulting solution was washed with 5% aqueous Na 2 CO 3 . The organic layer was isolated and dried over anhydrous Na 2 SO 4 , filtered and evaporated to dryness to afford the desired 4-(N-aminoalkyl)amino-7-chloroquinoline (6, Scheme 1); each compound 6 was then coupled to
the respective cinnamic acid in N,N-dimethylformamide (DMF), using O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) and N,N-diethyl-N-isopropylamine (DIEA) (Scheme 1): a
solution of cinnamic acid (1.1 eq, 0.22 mmol), TBTU (1.1 eq, 0.22 mmol), and 2.2eq of DIEA (68µL) in DMF was stirred at 0 ºC for 10 min; a solution of the appropriate compound 6 (1 eq, 0.2 mmol) in DMF was then added, and the reaction allowed to proceed at room temperature for 24 h; the mixture was diluted with DCM and the resulting solution was washed with 5% aqueous Na 2 CO 3 ; the organic layer was separated, dried over anhydrous Na 2 SO 4 , filtered and evaporated to dryness, and the crude product was purified by liquid chromatography on silica using EtOAc/MeOH 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 tert-butoxycarbonyl)aminocinnamic acid as above, to yield the N-tert-butoxycarbonyl (Boc) protected precursor (9e'), followed by removal of Boc through acidolysis with neat trifluoroacetic acid (TFA).
Spectral/analytical data on compounds 9,10 follow. 
4-(N-cinnamoylaminopropyl)amino-7-chloroquinoline (9a
4-[N-(p-methyl)cinnamoylaminopropyl]amino-7-chloroquinoline (9b):
4-[N-(p-isopropyl)cinnamoylaminopropyl]amino-7-chloroquinoline (9c
4-[N-(p-methoxy)cinnamoylaminopropyl]amino-7-chloroquinoline (9d
4-{N-[p-(N-tert-butoxycarbonyl)amino]cinnamoylaminopropyl}amino-7-chloroquinoline (9e').
White 
4-[N-(m-fluoro)cinnamoylaminopropyl]amino-7-chloroquinoline (9f
4-[N-(p-chloro)cinnamoylaminopropyl]amino-7-chloroquinoline (9h
4-[N-(p-methoxy)cinnamoylaminopentyl]amino-7-chloroquinoline (10b
Synthesis of compound 11.
4-[(7-chloroquinolin-4-yl)amino]butan-1-ol (11'). 1 eq of 4,7-dichloroquinoline (0.5g, 2.5mmol) was mixed with 4 eq of 4-aminobutan-1-ol (0.9g, 10mmol) in a round bottom flask, and reaction was allowed to proceed at 100 o C for 4 h. Then, DCM (25 mL) was added, followed by addition of 30% aqueous 
4-[N-(p-methoxy)cinnamoyloxypropyl]amino-7-chloroquinoline (11
4-[N-(p-isopropyl)cinnamoylaminopropyl]aminoquinoline (12).
Following the experimental procedure previously described for compounds 9 and 10, and starting from 4-chloroquinoline (0. 
4-[N-(p-methoxy)cinnamoylbutyl]aminopyridine (13).
In a round bottom flask put at 0 o C, 1.1 eq of pmethoxycinnamic acid (0.29 g, 1.5 mmol) was dissolved in DMF (2.5 mL) and activated by addition of 1.1 eq of TBTU (0.47 g, 1.5 mmol) and 2 eq of DIEA (454 µL); after 10 min, a solution of 1 eq of 13'
(0.22 g, 1.3 mmol) in DMF (2.5 mL) was added to the previous mixture and the reaction allowed to proceed for 24 h. Water (25 mL) was added to the reaction mixture and the desired product was extracted with DCM (3 × 25 mL); the organic extract was then washed with 5% aqueous Na 2 CO 3 (3 × 25mL), dried over anhydrous Na 2 SO 4 , filtered, and taken to dryness on a rotary evaporator; the residue was submitted to column chromatography on silica, using DCM/ 
Synthesis of compound 14.
N-(N-phthaloyl)aminobutylmorpholine (14''). 2 eq of morpholine (0.5g, 5.7 mmol) were reacted with 1 eq of 1-(N-phthaloyl)amino-4-bromobutane (0.8 g, 2.9 mmol) in refluxing DCM for 24 h, after which the reaction mixture was washed three times with 5% aqueous Na 2 CO 3 , dried over anhydrous Na 2 SO 4 , filtered, and led to dryness in a rotary evaporator; the residue was submitted to column chromatography on silica, using as eluent DCM:MeOH (8:2 v/v), to afford 14' as a white solid (0.53 g, 64%); mp=61- Inhibition of β β β β-hematin. The β-hematin inhibition assay was performed as previously described. 27, 28 Different concentrations (0.1 to 1 mM) of test compounds dissolved in DMSO were added in triplicate to 50 µL hemin chloride dissolved in DMSO (5.2 mg/mL). Negative controls were water and DMSO. β- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 centrifugation at 1700g for 5 min. At 24 h post-infection, medium was replaced by fresh medium containing the appropriate concentration of each compound. Inhibition of parasite development was measured 48 h after infection. The effect of the compounds on the viability of Huh-7 cells was assessed by the AlamarBlue assay (Invitrogen, UK), using the manufacturer's protocol.
In vivo assays
Evaluation of the in vivo antimalarial effects of HEFLECINS. Female Swiss Webster mice (n = 5)
were infected with 10 6 P. berghei-infected erythrocytes by ip injection. Two hours later the treatment was initiated with ip injections of 10, 30 and 100 mg/kg of compounds 7c, 7d, and 7h twice daily for 4 days.
Chloroquine was used as a positive control at 3, 10 and 30 mg/kg ip twice daily. For all murine malaria experiments, mice were evaluated daily for toxicity and for parasitemia by evaluation of Giemsa-stained blood smears. Animals were sacrificed when significant toxicity was identified or when parasitemias topped 50%. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60
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Heterocycle-cinnamic acid conjugates were synthesized and tested for their antimalarial properties, providing disclosure of new N-cinnamoylated chloroquine analogues with potent in vitro activity against both blood-and liver-stage malaria parasites. The compounds also displayed in vivo activity against rodent malaria.
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